These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20472682)

  • 1. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.
    Fujita M; Scheurer ME; Decker SA; McDonald HA; Kohanbash G; Kastenhuber ER; Kato H; Bondy ML; Ohlfest JR; Okada H
    Clin Cancer Res; 2010 Jul; 16(13):3409-19. PubMed ID: 20472682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes.
    Lu C; Klement JD; Ibrahim ML; Xiao W; Redd PS; Nayak-Kapoor A; Zhou G; Liu K
    J Immunother Cancer; 2019 Jun; 7(1):157. PubMed ID: 31228946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.
    Dey M; Chang AL; Miska J; Wainwright DA; Ahmed AU; Balyasnikova IV; Pytel P; Han Y; Tobias A; Zhang L; Qiao J; Lesniak MS
    J Immunol; 2015 Jul; 195(1):367-76. PubMed ID: 26026061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.
    Ohkuri T; Ghosh A; Kosaka A; Zhu J; Ikeura M; David M; Watkins SC; Sarkar SN; Okada H
    Cancer Immunol Res; 2014 Dec; 2(12):1199-208. PubMed ID: 25300859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.
    Fujita M; Zhu X; Ueda R; Sasaki K; Kohanbash G; Kastenhuber ER; McDonald HA; Gibson GA; Watkins SC; Muthuswamy R; Kalinski P; Okada H
    Cancer Res; 2009 Feb; 69(4):1587-95. PubMed ID: 19190335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
    Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
    Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
    Fujita M; Kohanbash G; Fellows-Mayle W; Hamilton RL; Komohara Y; Decker SA; Ohlfest JR; Okada H
    Cancer Res; 2011 Apr; 71(7):2664-74. PubMed ID: 21324923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of
    Schleicher U; Liese J; Justies N; Mischke T; Haeberlein S; Sebald H; Kalinke U; Weiss S; Bogdan C
    Front Immunol; 2018; 9():79. PubMed ID: 29459858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b
    Shime H; Matsumoto M; Seya T
    Cell Death Differ; 2017 Mar; 24(3):385-396. PubMed ID: 27834952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
    Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H
    Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of epidemiology, immunobiology, and translational research for brain tumors.
    Okada H; Scheurer ME; Sarkar SN; Bondy ML
    Ann N Y Acad Sci; 2013 May; 1284(1):17-23. PubMed ID: 23651189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells.
    Nakahara N; Pollack IF; Storkus WJ; Wakabayashi T; Yoshida J; Okada H
    Cancer Gene Ther; 2003 Jul; 10(7):549-58. PubMed ID: 12833135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective antitumor immunity against murine gliomas using dendritic cells transduced with hTERTC27 recombinant adenovirus.
    Gong HX; He L; Li XP; Wang YD; Li Y; Huang JJ; Wang Z; Xie D; Kung HF; Peng Y
    Oncol Rep; 2012 Apr; 27(4):1163-9. PubMed ID: 22210010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
    Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
    Fujita M; Zhu X; Sasaki K; Ueda R; Low KL; Pollack IF; Okada H
    J Immunol; 2008 Feb; 180(4):2089-98. PubMed ID: 18250414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
    Du B; Waxman DJ
    Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment.
    Cantini G; Pisati F; Mastropietro A; Frattini V; Iwakura Y; Finocchiaro G; Pellegatta S
    Cancer Immunol Immunother; 2011 Dec; 60(12):1739-50. PubMed ID: 21779877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
    Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
    PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma.
    Kobayashi T; Yamanaka R; Homma J; Tsuchiya N; Yajima N; Yoshida S; Tanaka R
    Cancer Immunol Immunother; 2003 Oct; 52(10):632-7. PubMed ID: 12827308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.